SCHEMBL19739072

SCHEMBL19739072

Cn1cc(-c2ccc(NC(=O)c3nc(NC(=O)OC(C)(C)C)cn3C)cc2)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
P2RY14 Q15391 1/20 0.39
MAP4K4 O95819 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
PSMB8 P28062 1/20 0.36
NAMPT P43490 1/20 0.36
PRKDC P78527 1/20 0.36
TTK P33981 1/20 0.35
HDAC1 Q13547 4/20 0.35
HDAC3 O15379 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
MAPK14 Q16539 1/20 0.35
HDAC10 Q969S8 1/20 0.35
AR P10275 1/20 0.34
ERBB2 P04626 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26073602 0.92 CYP17A1 (0.43) CYP17A1GSK3BDYRK1AP2RY14MAP4K4
SCHEMBL17230049 0.91 CYP17A1 (0.40) CYP17A1GSK3BDYRK1AP2RY14MAP4K4
SCHEMBL16710975 0.88 CYP17A1 (0.43) CYP17A1GSK3BDYRK1AP2RY14MAP4K4
SCHEMBL19614861 0.88 ERBB2 (0.41) GSK3BDYRK1ANAMPTHDAC1HDAC2
SCHEMBL22824915 0.88 GSK3B (0.45) GSK3BDYRK1ANAMPTHDAC1
SCHEMBL19739171 0.86 CYP17A1 (0.37) CYP17A1GSK3BDYRK1AP2RY14MAP4K4
SCHEMBL28458723 0.86 CYP17A1 (0.42) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL2029815 0.85 CYP17A1 (0.50) CYP17A1P2RY14MAP4K4CD274PSMB8
SCHEMBL16710976 0.85 HDAC1 (0.39) CYP17A1GSK3BDYRK1AMAP4K4CD274
SCHEMBL29790453 0.84 NAMPT (0.46) CYP17A1GSK3BDYRK1AP2RY14CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793885-B2 Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders IMMUNOGEN, INC. (US) 2023-10-24 US disclosed
EP-3475284-B1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF MERSANA THERAPEUTICS INC (US) 2022-11-02 EP disclosed
US-20200397914-A1 BENZODIAZEPINE DERIVATIVES IMMUNOGEN, INC. 2020-12-24 US disclosed
CN-111757757-A Pyrrolobenzodiazepine antibody conjugates 梅尔莎纳医疗公司 2020-10-09 CN disclosed
EP-3475284-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF Mersana Therapeutics, Inc. (US) 2019-05-01 EP disclosed
WO-2017223275-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. (US) 2017-12-28 WO disclosed
US-20170369453-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. 2017-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200397914-A1 BENZODIAZEPINE DERIVATIVES GABRA5, GABRA3, GABRA1 CYP17A1 114/4885GSK3B 125/4885DYRK1A 2150/4885
US-20170369453-A1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF CD79B, CLTB, FCGR3B CYP17A1 2930/4885GSK3B 3014/4885DYRK1A 1423/4885
US-11793885-B2 Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders MKI67, GABBR1, GABBR2 CYP17A1 99/4885GSK3B 158/4885DYRK1A 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.